Risankizumab
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Product Specifications
CAS Number
1612838-76-2
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
IL Receptor
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15400891 1 Vial
Lentiviral human LRP5L sgRNA gene knockout kit - Lentiviral human LRP5L sgRNA gene knockout kit (100)
Ask
View Details 056071-01 10 µg
Activity Regulated Cytoskeleton Associated Protein (ARC), Recombinant, Rat, His-Tag
Ask
View Details 056071-02 50 µg
Activity Regulated Cytoskeleton Associated Protein (ARC), Recombinant, Rat, His-Tag
Ask
View Details 056071-03 100 µg
Activity Regulated Cytoskeleton Associated Protein (ARC), Recombinant, Rat, His-Tag
Ask
View Details 056071-04 200 µg
Activity Regulated Cytoskeleton Associated Protein (ARC), Recombinant, Rat, His-Tag
Ask
View Details